We’re on a mission…

Clinical Trials

Q-Metrx provides quality controlled services for electro-physiological data collection, quantitative analysis, data management, statistical analysis, and publication of findings.

Q-Metrx has experience with subjects ranging from

  • Healthy Normal Volunteers

To people suffering from:

  • Alzheimer’s Disease
  • Essential Tremor
  • Insomnia
  • Major Depressive Disorder
  • Narcolepsy
  • Periodic Limb Movement Syndrome/Disorder (PLMS/D)
  • Restless Legs Syndrome (RLS)
  • Schizophrenia
  • Seizure Disorders
  • Sleep Apnea

Q-Metrx has clinical trial experience with drugs/compounds and medical devices for the treatment of various conditions, diseases and disorders.

Publications

We actively carry out research and publish on topics in clinical neuroscience and psychology.

Publications
Ereshefsky et al.
Nations et al.
Shambroom et al.
Johnstone et al.
Johnstone, Jack
Fava et al.
Johnstone et al.
Johnstone et al.

 

Electroencephalography Capabilities

With the aid of the pharmaco-EEG, essential information can be obtained in early drug development regarding CNS penetration and efficacy of new substances as follows:

  • Evidence for substance penetration (bioavailability) in the CNS on the basis of PD changes. In addition to the classic PK parameters (e.g., tmax, Cmax, AUC and t½), EEG/ERP parameters can be used to demonstrate time- and dose-effect correlations.
  • Proof of CNS effects of a substance by comparison of quantitative EEG (qEEG/ERP) changes between pre- and post-dose measurements.
  • Characterization of psychotropic properties of a substance by comparison with psychotropic class effects of marketed drugs. Classic psychotropic drugs show typical pharmaco-EEG profiles, thus allowing assignment of new substances in many cases.
  • Determination of new substance’s therapeutic window. The dose at which a new substance can be statistically distinguished from placebo, and at which it displays a psychotropic effect in comparison with a reference preparation, is often a therapeutically effective dose.
  • Proof of adverse CNS effects of non-psychotropic substances (e.g., sedation produced by anti-hypertensive drugs or anti-histamines, changed convulsion threshold due to antibiotics).
  • Determination of the bioequivalence of two different galenic dosage forms by quantitative comparison of CNS changes.